About Vium
Vium is a company based in San Mateo (United States) founded in 2013 was acquired by Recursion in July 2020. Vium has raised $86 million across 7 funding rounds from investors including Recursion Pharmaceuticals, Lux Capital and DCVC. Vium operates in a competitive market with competitors including Scientist.com, Clustermarket, antibodies-online, Gongyingshi and Data Lake, among others.
- Headquarter San Mateo, United States
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$86 M (USD)
in 7 rounds
-
Latest Funding Round
$24 M (USD), Series B
Jun 21, 2018
-
Investors
Recursion Pharmaceuticals
& 6 more
-
Employee Count
Not available
-
Acquired by
Recursion
(Jul 28, 2020)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
People of Vium
Unlock access to complete
Unlock access to complete
Funding Insights of Vium
Vium has successfully raised a total of $86M across 7 strategic funding rounds. The most recent funding activity was a Series B round of $24 million completed in June 2018. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Vium
Vium has secured backing from 7 investors, including venture fund investors. Prominent investors backing the company include Recursion Pharmaceuticals, Lux Capital and DCVC.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Seed and early-stage technology companies are funded by Lux Capital.
|
Locked | Locked | Locked | |
|
Venture capital firm focused on multiple sectors
|
Locked | Locked | Locked | |
|
Venture capital fund focused on early-stage biotech, life sciences, IT, and multiple sectors
|
Locked | Locked | Locked |
Investor details for Vium
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Vium
Investment portfolio details for Vium
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Vium
Detailed financials for Vium
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Vium Comparisons
Peer comparison for Vium
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Vium
Vium operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Scientist.com, Clustermarket, antibodies-online, Gongyingshi and Data Lake, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Online marketplace for preclinical drug development services is operated.
|
|
| Locked | Locked | Locked |
Online sharing platform for life scientists to list, discover and book resources within their institution or cluster
|
|
| Locked | Locked | Locked |
Online store for selling antibody kits
|
|
| Locked | Locked | Locked |
B2B procurement platform for R&D labs
|
|
| Locked | Locked | Locked |
Developer of a centralized repository platform for medical research
|
Detailed competitors of Vium
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Vium
Complete news archive for Vium
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Vium
Vium was founded in 2013 and raised its 1st funding round 1 year after it was founded.
Vium is headquartered in San Mateo, United States. It is registered at San Mateo, California, United States.
Vium is a funded company, having raised a total of $86M across 7 funding rounds to date.
Vium (under the stealth name Mousera) has developed a living informatics platform for preclinical in vivo drug research. Its products The Vium Digital Vivarium, Vium Cloud, and online Research Suite aids scientists with bioengineered research models and serves the customers in the spectrum of biotechnology, pharmaceutical, and computational drug discovery companies, academia and novel therapeutic labs. It also develops best-in-class animal models with automated, digital efficacy and health metrics across a variety of therapeutic areas such as RA, MS, Lupus, Health Span aging biology.
Vium's top competitors include Scientist.com, Clustermarket and antibodies-online.
Vium has 7 investors. Key investors include Recursion Pharmaceuticals, Lux Capital, DCVC, Dolby Family Ventures, and Founders Fund.